drugset / Trial / NCT00313781
Study of CP-751,871 in Combination With Docetaxel and Prednisone in Patients With Hormone Insensitive Prostate Cancer (HRPC)
RandomizedParallel-groupOpen-labelTreatment
Summary
To test the efficacy of CP-751,871 combined with docetaxel and prednisone in the treatment of prostate cancer that is refractory to hormone therapy
Timeline
- Start
- 2006-05
- Primary completion
- 2011-04
- Completion
- 2011-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Figitumumab | Monoclonal antibody | 20 mg/kg | Intravenous |
| Comparator | Docetaxel | Small molecule | 75 mg/m2 | Intravenous |
| Comparator | Prednisone | Other / unclassified | 5 mg | — |